To further validate synthetic lethality of TFAP4 to MYCN amplification, we examined three MYCN-amplified human neuroblastoma cell lines (BE(2)C, NGP and SK-N-DZ) and three non-MYCN-amplified human neuroblastoma cell lines (CHLA-255, CHLA-20, and SH-SY5Y). The gene discussed is TFAP4; the disease is neuroblastoma.